May  2022

No Study Name/Phase Type Sponsor Population (Gender/Age) Enrolled / (Target if still enrolling) Period
1 HVTN 705/Phase IIb HIV Vaccine Janssen/HVTN ♀18-35 yrs 144 2018 – 2021
2 NC008/Phase IIc TB Treatment TB Alliance ♂/♀≥18 33 2018 – 2020
3 PrEPARE Study/PrEP Rollout PrEP RTI ♀16-24 yrs  n/a 2019 – 2021
4 R01 AI147681 KHARITUWE TB MIGRATION STUDY TB Tracing John Hopkins University ♂/♀ 0-99 yrs target 7200 2020 – 2025
5 C3671008 RSV Vaccine Pfizer ♀   ≥18 and ≤49 target 120 2020 – 2023
6 VAC31518COV3001 Covid Vaccine Janssen ♂+♀≥18 and ≤60 & ≥60 306 2020 – 2022
7 CoVPN5001 / HVTN5001 Covid observational CoVPN ♂+♀ ≥18 Target 15 2020 – 2021
8 ACTIV-2 A5401 COVID IV Infusion PPD ♂+♀ ≥18 Target 75 2021 – 2022
9 212171 (RSV MAT-009) RSV Vaccine GSK ♀  18 – 49 Target 250 2021 – 2023
10 MK8591-022 IMPOWER Oral PrEP MSD ♀   18 – 45 Target 300 2021 – 2025
11 SRC Geo-Mapping project Behavioural SRC n/a n/a 2021
12 HVTN RAMP Behavioural HVTN MSM &Transgender ♂ ≥18; Transgender ♀ ≥18 200 May 2021 – May 2022
13 HVTN 702/705 Mapping Behavioural SRC ♂/♀18-35 yrs n/a 2020-2021
14 Sisonke VAC31518COV3012 Phase 3b Covid Vaccine Janssen ♂+♀
18-65
600 000 Feb/ 2021 – Feb/2023
15 STI Zoli Study Phase 3 STI Treatment Oral/Intramuscular GARDP ≥ 12♂/♀ 80 Nov/2021 – Dec/2021
16 PrEP (Adolescent Girls and Young Women) Phase 3 HIV PrEP study Gilead Cisgender ♀
16 – 35
200 Nov/2021 – Jun/2022
17 HVTN 139 Phase 1 HIV Vaccine Study HVTN ♂+♀18 through to 50 years 6 Nov/2021 – Dec/2023
18 Pfizer RSV Phase 3 RSV Vaccine Pfizer ♂+♀
≥ 60
100 Nov/2021 – Dec/2022
19 Gates MRI TBV02-EO1 Epidemiology Bill and Melinda Gates ♂+♀15 – 34 160 Jan 2022 – Jun 2025
20 VAC31518COV3003 Covid Vaccine Janssen ♂+♀18 -55 100 Feb 2022- May 2023
21 GO-012 Covid Vaccine Gritstone Bio ♂+♀18 – 64 120 Mar 2022 – Mar 2023
 22 323-201-00006_Otsuka Trial – 2b/c TB Oral treatment Study Clindev ♂+♀ 18-65 20 APR/2022-APR/2024